As Sanofi posts yet another stellar set of sales figures for its autoimmune mega-blockbuster Dupixent, CEO Paul Hudson has told Scrip that growth is set to keep soaring despite the arrival of competition in the US from oral JAK inhibitors in its key indication of atopic dermatitis.
Sanofi Unruffled By JAK Threat To Dupixent
As Blockbuster Hits €5.25bn In 2021 Sales
CEO Paul Hudson tells Scrip that in an atopic dermatitis market that has a standard of care like Dupixent, "it's hard to justify the role of a JAK unless somebody has, frankly, failed everything else."
